Nano-cocktail overcomes multidrug-resistance for ovarian cancer therapy
纳米鸡尾酒克服了卵巢癌治疗的多重耐药性
基本信息
- 批准号:8958102
- 负责人:
- 金额:$ 36.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-01 至 2019-06-30
- 项目状态:已结题
- 来源:
- 关键词:2-methoxyestradiolAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsArtsBindingBiodistributionBiomedical EngineeringBiomedical ResearchCancer EtiologyCell ProliferationCellsCessation of lifeChemistryChemotherapy-Oncologic ProcedureClinical TrialsDeath RateDevelopmentDiagnosisDiseaseDoctor of PharmacyDoxorubicinDrug CarriersDrug CombinationsDrug KineticsDrug resistanceERBB2 geneEncapsulatedEnsureEnvironmentEquipmentExhibitsGynecologicHead and Neck NeoplasmsKineticsLaboratoriesLigandsMalignant NeoplasmsMalignant neoplasm of ovaryMinnesotaMinorityModelingModificationMonitorMulti-Drug ResistanceMusNanoGelNatureNeoplasm MetastasisNormal CellOperative Surgical ProceduresOxidation-ReductionPaclitaxelPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacy StudentsPolymersProgram ReviewsPropertyRecruitment ActivityRegimenRelapseResearchResearch TrainingResistanceScienceScientistSerumSolid NeoplasmSouth CarolinaStagingStudentsSurvival RateSystemTherapeutic EffectThinkingToxic effectTrainingTumor DebulkingTumor TissueUnited StatesUniversitiesWomanXenograft ModelXenograft procedureantitumor effectbasecancer cellcancer stem cellcancer therapychemotherapycollegedensityeffective therapyexperiencefemale reproductive systemfight againstgraduate studentimprovedintraperitonealkillingsmortalitymouse modelnanonanoparticlenanoparticulatenext generationnovelovarian neoplasmprogramspublic health relevancereceptorresponsesigma-2 receptorskillssubcutaneoussuccesstooltreatment strategytumortumor growthundergraduate studentunderrepresented minority student
项目摘要
DESCRIPTION (provided by applicant): Ovarian cancer is the fifth most common cause of cancer-related deaths in women and results in more deaths than any other cancer of the female reproductive system. The primary reasons for the high death rate of ovarian cancer are multidrug-resistance and the metastatic nature of cancer stem cells (CSCs). Since conventional anticancer drugs cannot kill drug resistant cells and eliminate CSCs, a novel effective treatment for ovarian cancer is urgently needed. The objective of this research is to develop a dual targeted nano-cocktail (DTNC) for safe and effective ovarian cancer therapy. We hypothesize that: (a) the low density combination of two targeting moieties can minimize the non-specific targeting effect while ensuring that the drug carrier will be exclusively localized in the tumor tissue and taken up by cancer cells through hetero-multivalent binding; (b) the drug combination of different anticancer mechanisms will exhibit synergistic effects and eradicate ovarian tumor. Our project has three specific aims. In Aim 1, we will explore drug combinations for optimal cancer cell proliferation inhibitory effect. Aim 2 will examine the dual-ligand targeting effect on
the biodistribution of DTNC and investigate its pharmacokinetic properties. Aim 3 will evaluate the tumor growth inhibitory effect of DTNC in both subcutaneous xenograft and orthotopic intraperitoneal tumor mouse models and examine its systemic toxicity. Over the course of this 3-year project, undergraduate, graduate, and Doctor of Pharmacy students will participate in the project in various levels, from hands-on skills with state-of-arts equipment to creative thinking. Undergraduate students will be recruited from the highly selective Honors College and Biomedical Engineering program of the University of South Carolina, as well as Morris College, a Historically Black, coeducational college. Therefore, the development of DTNC will provide clinicians with a more effective tool in fighting against ovarian cancer as well as offer precious biomedical research training opportunities for students, especially underrepresented minority students.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Peisheng Xu其他文献
Peisheng Xu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Peisheng Xu', 18)}}的其他基金
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
癌细胞选择性杀伤纳米颗粒用于晚期卵巢癌治疗
- 批准号:
10680585 - 财政年份:2022
- 资助金额:
$ 36.63万 - 项目类别:
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment
癌细胞选择性杀伤纳米颗粒用于晚期卵巢癌治疗
- 批准号:
10453919 - 财政年份:2022
- 资助金额:
$ 36.63万 - 项目类别:
The development of a multifunctional nanoenzyme for AD treatment
用于AD治疗的多功能纳米酶的开发
- 批准号:
10611675 - 财政年份:2022
- 资助金额:
$ 36.63万 - 项目类别:
Brain targeted nanoparticle for Alzheimer's disease therapy
用于治疗阿尔茨海默病的脑靶向纳米颗粒
- 批准号:
9329544 - 财政年份:2017
- 资助金额:
$ 36.63万 - 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
- 批准号:
8653312 - 财政年份:
- 资助金额:
$ 36.63万 - 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
- 批准号:
8885856 - 财政年份:
- 资助金额:
$ 36.63万 - 项目类别:
Dual responsive nanoparticle for brain targeted drug delivery
用于大脑靶向药物输送的双响应纳米颗粒
- 批准号:
9061734 - 财政年份:
- 资助金额:
$ 36.63万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 36.63万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 36.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 36.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 36.63万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 36.63万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 36.63万 - 项目类别:














{{item.name}}会员




